Head-to-head · WeighScore
Rebody Health vs Tablet Health
The verdict
Rebody Health takes it — 67.7/100 to 47.6/100.
Rebody Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Rebody Health (rebodyhealth.com), operated by Compound Technologies Inc., is a transparent-pricing GLP-1 and wellness telehealth service that publishes prices up front.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Rebody Health | Tablet Health |
|---|---|---|
| WeighScore | 67.7/100 | 47.6/100 |
| Grade | C | C |
| Scorecard rank | #159 | #495 |
| Semaglutide | $200/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $250/mo (starting dose, compounded) | Not disclosed |
| Coverage | 47 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #159 · C
Strengths
- Publishes transparent, dose-based pricing up front on a public pricing page, so you can see costs without signing up
- Offers compounded semaglutide and tirzepatide as both weekly injections and daily oral 'melt' tablets
- Also carries brand-name Wegovy and Zepbound for patients who want FDA-approved products
- Clear plan-term vs dose-tier structure; the refill price is shown before each shipment, plus $50 off the first month
- Names its operating company (Compound Technologies Inc.) and references LegitScript approval
Where it loses points
- Individual compounding pharmacies are not named on the marketing site
- Not available in Massachusetts, Rhode Island, or Vermont
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- Dose-scaled pricing means the monthly cost can rise as your prescribed dose increases
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.